NCT05082116 - Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions

Haemophilia A

Interventions

DRUG

turoctocog alfa pegol (N8-GP)

N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks

Trial Locations (8)

Beijing Children's Hospital，Capital Medical University, Beijing

Jinan Central Hospital, Ji'nan

Institute of hematology and Blood Diseases Hospital, Tianjin, Tianjin

Fujian Medical University Union Hospital-Hematology, Fuzhou

Haemotology, Nanfang Hospital, Southern Medical University, Guangzhou

The Affiliated hospital of Guizhou Medical University-Hemato, Guiyang

The Second Affiliated Hospital of Kunming Medical University, Kunming

Qinghai Provincial People's Hospital, Xining